FDA, DEA Blame Demand, Drug Makers for ADHD Med Shortage

In a letter to the public the FDA and the DEA contend that unprecedented demand, potential overprescribing, and underproduction are the primary reasons for the national shortage of stimulants to treat ADHD.
Medscape Medical News

source https://www.medscape.com/viewarticle/995079?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?